Cost/benefit aspects on thromboprophylaxis

David Bergqvist, Thomas Mätzsch

Research output: Contribution to journalArticlepeer-review


Several studies have shown thromboprophylaxis of any kind to be more cost-effective than no prophylaxis or general diagnostic surveillance and selective treatment. Little has been written on low molecular weight heparins from the cost-effectiveness point of view. This preliminary study shows low molecular weight heparin to be more cost-effective than standard low-dose heparin in most situations of prophylaxis.
Original languageEnglish
Pages (from-to)15-19
Issue numberSuppl. 1
Publication statusPublished - 1993

Bibliographical note

The information about affiliations in this record was updated in December 2015.
The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)

Subject classification (UKÄ)

  • Clinical Medicine


Dive into the research topics of 'Cost/benefit aspects on thromboprophylaxis'. Together they form a unique fingerprint.

Cite this